Globe on Big Pharma R&D Failure
3 Comments
Recent Posts
Everything You Wanted to Know About a Kids’ Social Media Ban (But Were Rightly Afraid to Ask): A FAQ on Age Verification and Mandated ID for Everyone 
Bill C-22’s Clause-by-Clause Problem: The Government Includes Agencies Seeking Lawful Access Powers But Blocks the Privacy Commissioner’s Return 
You Can’t Put the Toothpaste Back in the Tube: Why the Government’s Reported “Temporary” Plan for a Kids’ Social Media Ban Would Mean Mandated ID for Everyone 
The Law Bytes Podcast, Episode 271: Taking Stock of a Wild Week in Canadian Digital Policy With the Online Streaming Reversal, AI Strategy Release, and Lawful Access Review 
Canadian American Business Council on Bill C-22: It “Threatens Our Bilateral Partnership on Data Security”
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?